VAIA
RLMD icon

Virtus Alternative Investment Advisers’s Relmada Therapeutics RLMD Stock Holding History

Virtus Alternative Investment Advisers’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-150
Closed -$5K – 177
2020
Q4 		$5K Sell
150
-145
-49% -$4.98K 0.07% 265
2020
Q3 		$11K Buy
+295
New +$11.4K 0.2% 194

Other funds holding RLMD

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Virtus Alternative Investment Advisers's RLMD Position: Q1 2021 in Review

Virtus Alternative Investment Advisers sold out of Relmada Therapeutics (RLMD) in Q1 2021, closing a stake of 150 shares — an estimated $5K sold.

Virtus Alternative Investment Advisers first reported a position in RLMD in Q3 2020 and held it in 2 quarters. The position peaked at $11K in Q3 2020. 82 funds tracked by Wall St. Rank hold RLMD as of Q1 2021.

  • Virtus Alternative Investment Advisers reported no remaining Relmada Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Virtus Alternative Investment Advisers sold 150 Relmada Therapeutics shares in Q1 2021, an estimated $5K.
  • Virtus Alternative Investment Advisers first reported a position in Relmada Therapeutics in Q3 2020 and held it in 2 quarters.
  • Virtus Alternative Investment Advisers's Relmada Therapeutics position peaked at $11K in Q3 2020.
  • 82 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2021.

Based on Virtus Alternative Investment Advisers's 13F filing for Q1 2021.